1. Home
  2. NOAH vs DCTH Comparison

NOAH vs DCTH Comparison

Compare NOAH & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOAH
  • DCTH
  • Stock Information
  • Founded
  • NOAH 2005
  • DCTH 1988
  • Country
  • NOAH China
  • DCTH United States
  • Employees
  • NOAH N/A
  • DCTH N/A
  • Industry
  • NOAH Investment Managers
  • DCTH Medical/Dental Instruments
  • Sector
  • NOAH Finance
  • DCTH Health Care
  • Exchange
  • NOAH Nasdaq
  • DCTH Nasdaq
  • Market Cap
  • NOAH 618.3M
  • DCTH 630.4M
  • IPO Year
  • NOAH 2010
  • DCTH N/A
  • Fundamental
  • Price
  • NOAH $10.29
  • DCTH $16.21
  • Analyst Decision
  • NOAH Hold
  • DCTH Strong Buy
  • Analyst Count
  • NOAH 3
  • DCTH 4
  • Target Price
  • NOAH $12.50
  • DCTH $24.00
  • AVG Volume (30 Days)
  • NOAH 81.2K
  • DCTH 610.5K
  • Earning Date
  • NOAH 05-28-2025
  • DCTH 05-08-2025
  • Dividend Yield
  • NOAH 20.61%
  • DCTH N/A
  • EPS Growth
  • NOAH N/A
  • DCTH N/A
  • EPS
  • NOAH 0.96
  • DCTH N/A
  • Revenue
  • NOAH $353,619,651.00
  • DCTH $53,850,000.00
  • Revenue This Year
  • NOAH N/A
  • DCTH $141.47
  • Revenue Next Year
  • NOAH $6.37
  • DCTH $49.31
  • P/E Ratio
  • NOAH $10.69
  • DCTH N/A
  • Revenue Growth
  • NOAH N/A
  • DCTH 1068.87
  • 52 Week Low
  • NOAH $7.14
  • DCTH $6.33
  • 52 Week High
  • NOAH $14.90
  • DCTH $18.23
  • Technical
  • Relative Strength Index (RSI)
  • NOAH 60.74
  • DCTH 58.15
  • Support Level
  • NOAH $9.31
  • DCTH $16.02
  • Resistance Level
  • NOAH $10.91
  • DCTH $17.29
  • Average True Range (ATR)
  • NOAH 0.36
  • DCTH 0.99
  • MACD
  • NOAH 0.09
  • DCTH -0.03
  • Stochastic Oscillator
  • NOAH 61.25
  • DCTH 49.63

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: